Abstract
Patients with Eastern Cooperative Oncology Group performance status (PS) of 2 or greater were excluded from immune checkpoint inhibitor (ICI) trials in non-small cell lung cancer (NSCLC). We aim to assess how PD-L1 status affects survival on ICI monotherapy versus chemotherapy in patients with trial-ineligible PS using nationwide real-world data.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
